Effects of fasudil on hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 7, 2014, Pages 959-964

  Sun, X Z ^a   Tian, X Y ^a   Wang, D W ^b   Li, J ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Fasudil; Pulmonary arterial hypertension (PAH); Pulmonary vascular remodeling

Indexed keywords

COLLAGEN FIBER; FASUDIL; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; PROTEIN KINASE INHIBITOR; RHO KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; LUNG BLOOD VESSEL; MALE; NONHUMAN; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; TRANSMISSION ELECTRON MICROSCOPY; ANALOGS AND DERIVATIVES; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; ARTERIOLE; BLOOD PRESSURE; CAROTID ARTERY; DRUG EFFECTS; HYPERTENSION, PULMONARY; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE; VASCULAR REMODELING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; ANOXIA; ARTERIOLES; BLOOD PRESSURE; CAROTID ARTERIES; HYPERTENSION, PULMONARY; LUNG; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; VASCULAR REMODELING;

EID: 84902185458     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. CRUZ JA, BAUER EM, RODRIGUEZ A.I., GANGOPADHYAY A., ZEINEH NS, WANG Y, SHIVA S, CHAMPION H.C., BAUER PM. Chronic hypoxia induces right heart failure in caveolin-1-/- mice. Am J Physiol Heart Circ Physiol 2012; 302: H2518-H2527.
2. SCHANNWELL CM, STEINER S, STRAUER BE Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007; 5: 591-602. (Pubitemid 351350581)
3. SATOH K, FUKUMOTO Y, SHIMOKAWA H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011; 301: H287-H296.
4. MATHEW R. Pulmonary hypertension: current therapy and future prospects. Cardiovasc Hematol Agents Med Chem 2011; 9: 165-182.
5. DUONG-QUY S., RIVIERE S, BEI Y., DUONG-NGO C, LE-DONG NN, HUA-HUY T, DINH-XUAN AT. Pulmonary hypertension: From molecular pathophysiology to haemodynamic abnormalities. Rev Mal Respir 2012; 29: 956-970.
6. RAJA SG. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension. Recent Pat Cardiovasc Drug Discov 2012; 7: 100-104.
7. SAKAO S, TATSUMI K. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiration 2011; 81: 253-261.
8. JONES JE, WALKER JL, SONG Y, WEISS N., CARDOSO WV, TUDER RM, LOSCALZO J, ZHANG Y Y. Effect of 5-lipoxy-genase on the development of pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2004; 286: H1775-H1784. (Pubitemid 38525466)
9. CUIFEN Z, LIJUAN W, LI G., WEI X, ZHIYU W, FUHAI L. Changes and distributions of peptides derived from proadrenomedullin in left-to-right shunt pulmonary hypertension of rats. Circ J 2008; 72: 476-481. (Pubitemid 351600646)
10. XU EZ, KANTORES C, IVANOVSKA J., ENGELBERTS D, KAVANAGH B P, MCNAMARA PJ, JANKOV RP. Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010; 299: H1854-H1864.
11. JEFFERY TK, MORRELL NW Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45: 173-202. (Pubitemid 36139815)
12. BUDHIRAJA R, TUDER RM, HASSOUN PM Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165. (Pubitemid 38114133)
13. STENMARK KR, MCMURTRY IF Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: A time for reappraisal? Circ Res 2005; 97: 95-98. (Pubitemid 41033463)
14. EARLEY S, NELIN LD, CHICOINE L.G., WALKER BR Hy-poxia-induced pulmonary endothelin-1 expression is unaltered by nitric oxide. J Appl Physiol 2002; 92: 1152-1158. (Pubitemid 34670974)
15. RHODES CJ, DAVIDSON A, GIBBS J.S., WHARTON J., WILKINS MR Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121: 69-88.
16. FUKUMOTO Y, SHIMOKAWA H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
17. BALIGA RS, MACALLISTER RJ, HOBBS AJ New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol 2011; 163: 125-140.
18. ANTONIU SA. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin Ther Targets 2012; 16: 355-363.
19. SETO M. Development of Rho kinase inhibitors for pulmonary arterial hypertension. Nihon Yakuri-gaku Zasshi 2012; 139: 251-255.
20. BARMAN SA, ZHU S, WHITE RE RhoA/Rho-kinase signaling: A therapeutic target in pulmonary hypertension. Vasc Health Risk Manag 2009; 5: 663-671.
21. BADEJO AM J.R., DHALIWAL JS, CASEY D.B., GALLEN TB, GRECO AJ, KADOWITZ PJ Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. Am J Physiol Lung Cell Mol Physiol 2008; 295: L828-L836.
22. FUJITA H, FUKUMOTO Y, SAJI K., SUGIMURA K, DEMACHI J, NAWATA J., SHIMOKAWA H. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144-149.